Policy / Pricing Trump backs psychedelics for mental health in new executive order pharminent April 20, 2026
Regulatory MSD secures EC approval for Enflonsia to prevent infant RSV infection pharminent April 20, 2026
Manufacturing Magazine: Digital twins become the new battleground for CDMOs pharminent April 20, 2026
Commercial Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool pharminent April 17, 2026
Commercial Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch pharminent April 17, 2026
Other S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting pharminent April 17, 2026
Policy / Pricing RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media pharminent April 17, 2026
Clinical Data Novo may have muscle advantage over Lilly in weight-loss race: preprint pharminent April 17, 2026
Regulatory Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
Policy / Pricing Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director pharminent April 16, 2026
Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes pharminent April 16, 2026
Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials pharminent April 16, 2026
Clinical Data Roche to start new Elevidys study following setback in Europe pharminent April 16, 2026
Clinical Data Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns pharminent April 16, 2026
M&A / Deals Obesity’s explosive growth continues as Q1 deals exceed total 2025 value pharminent April 16, 2026
Policy / Pricing FDA accelerated approval path needs improvement, says ICER pharminent April 16, 2026
Commercial Revolution doubles stock offering target to $2B following pancreatic cancer win pharminent April 16, 2026
M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026